Pre-made Urelumab benchmark antibody ( Whole mAb, anti-TNFRSF9/CD137 therapeutic antibody, Anti-ILA/4-1BB/CDw137 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-604

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-604 Category Tag

Product Details

Pre-Made Urelumab biosimilar, Whole mAb, Anti-TNFRSF9/CD137 Antibody: Anti-ILA/4-1BB/CDw137 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Urelumab (BMS-663513 or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer and solid tumors.

Products Name (INN Index)

Pre-Made Urelumab biosimilar, Whole mAb, Anti-TNFRSF9/CD137 Antibody: Anti-ILA/4-1BB/CDw137 therapeutic antibody

INN Name

Urelumab

Target

TNFRSF9

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Active

100% SI Structure

6mhr:AB:DE

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2010

Companies

Bristol-Myers Squibb,National Cancer Institute (USA),Ono Pharmaceutical,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,University of Chicago,Medarex

Conditions Approved

NA

Conditions Active

Non-Hodgkin's lymphoma,Solid tumours,Glioblastoma,Multiple myeloma

Conditions Discontinued

Colorectal cancer,Head and neck cancer,Malignant melanoma,Non-small cell lung cancer

Development Tech

Medarex UltiMAb Mouse

Previous Name

NA

Gm Offical Target Name

TNFRSF9

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide